RARE DISEASE
Sheehan syndrome
Sheehan syndrome
Sheehan syndrome
Drug discovery
1
drug
With orphan designation
Overview
Sheehan syndrome is a rare postpartum hypopituitarism caused by pituitary necrosis due to severe obstetric hemorrhage, resulting in impaired hormone production (ACTH, TSH, GH, prolactin, gonadotropins) [1][4][15]. Diagnosis relies on clinical history, hormonal assays, and pituitary MRI [6][12]. Treatment involves lifelong hormone replacement therapy with corticosteroids, levothyroxine, and sex steroids [3][6][15].
Therapies
Hormone replacement: Glucocorticoids (hydrocortisone), levothyroxine, estrogen/progesterone until menopause [3][6]
Growth hormone therapy: Improves body composition/bone density but often underutilized due to cost [5][15]
Monitoring: Regular cortisol adjustment during stress events to prevent adrenal crisis [8][15]
Categories: rare endocrine diseases
Research Papers
78 drug discovery papers about Sheehan syndrome, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
78 drug discovery papers about Sheehan syndrome, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-07-25 | Two Decades of Endocrine Silence: Severe Hyponatremia Presenting as Late-Onset Sheehan Syndrome
Sheehan syndrome is a rare but potentially fatal complication of postpartum hemorrhage caused by ischemic necrosis of the anterior pituitary gland. Although its incidence has decreased in countries with comprehensive obstetric care systems, it remains a significant cause of panhypopituitarism in regions lacking timely and adequate access to perinatal care. The clinical challenge lies in its insidious presentation: symptoms develop slowly and gradually, and the diagnosis may remain unrecognized for decades. We report the case of a 52-year-old woman who presented with a one-year history of progressive decline in general health, characterized by debilitating asthenia, somnolence, decreased appetite, and an unintentional 13-kg weight loss. Her obstetric history provided the crucial diagnostic clue: 21 years prior, her last delivery - an initially unattended home birth - was complicated by a retained placenta and severe hemorrhage, followed by total agalactia and permanent secondary amenorrhea. Initial laboratory evaluation revealed severe hyponatremia (119 mmol/L), normocytic anemia, and biochemical evidence of central hypothyroidism and adrenal insufficiency. Magnetic resonance imaging (MRI) confirmed an empty sella turcica. Sequential hormone replacement therapy was initiated - administering glucocorticoids before levothyroxine - resulting in the normalization of serum sodium levels and significant clinical improvement. The clinical triad of postpartum hemorrhage, agalactia, and secondary amenorrhea constitutes a critical diagnostic red flag. Timely recognition of Sheehan syndrome is essential not only for resolving acute complications such as hyponatremia, driven by secondary hypothyroidism and hypocortisolism, but also for preventing cardiometabolic complications and severe osteoporosis with a high fracture risk associated with untreated chronic hypopituitarism.
2025-11-01 | SHEEHAN SYNDROME PRESENTING WITH SEVERE HYPONATREMIA: A CASE REPORT
Sheehan syndrome, characterized by pituitary necrosis secondary to postpartum hemorrhage, results in partial or complete hypopituitarism. Diagnosis is often delayed due to its nonspecific clinical manifestations; however, the condition can lead to life-threatening complications such as hyponatremia. We present the case of a 56-year-old woman admitted with symptomatic severe chronic hyponatremia, who was subsequently diagnosed with panhypopituitarism caused by Sheehan syndrome. The patient was successfully managed with hypertonic saline infusion and hormone replacement therapy (levothyroxine and hydrocortisone). This case emphasizes the importance of obtaining a thorough obstetric history and maintaining a high index of suspicion for Sheehan syndrome in middle-aged women presenting with unexplained hyponatremia.
2025-10-04 | Complete Atrioventricular Block: An Exceedingly Rare Manifestation of Pituitary Crisis in Sheehan Syndrome
This study reports the first case of Sheehan syndrome presenting with complete atrioventricular (AV) block. This life-threatening arrhythmia, associated with glucocorticoid deficiency, can be reversed by glucocorticoid replacement therapy. A 53-year-old female patient presented with complete AV block, elevated myocardial enzyme levels, and hyponatremia. Initially misdiagnosed as having fulminant myocarditis, she received high-dose methylprednisolone therapy, which corrected the complete AV block.
2025-10-01 | Recurrent Symptomatic Hyponatremia Revealing a Late Diagnosis of Sheehan Syndrome and Effectively Treated With Levothyroxine: A Case Report and Brief Review of Literature
ABSTRACT In women with a history of postpartum hemorrhage presenting with chronic symptoms such as hyponatremia, amenorrhea, weight loss, or cold intolerance, suspect Sheehan's syndrome. Early diagnosis and prompt hormonal replacement therapy are essential for reversing complications and improving quality of life. Prioritize evaluation of pituitary function in these patients to ensure timely intervention.
2025-09-29 | Table 1_A case report of acute Sheehan syndrome with a review of 29 existing reports from 1990 to 2024: is it still considered a rare disease?.xlsx
Background Sheehan's syndrome (SS) can occur as a consequence of massive postpartum hemorrhage (PPH). Although traditionally considered rare, acute SS may be underestimated, especially in resource-limited settings, where even minor obstetric complications other than the commonly recognized uterine atony could lead to significant clinical consequences. Case report A 32-year-old pregnant woman (gravida 1, para 0) at 37 weeks and 6 days of gestation developed massive PPH complicated by hemorrhagic shock, cardiac arrest, and an emergent hysterectomy, with an estimated blood loss of 20 L. Despite initial stabilization, the patient experienced acute delirium and hyperpyrexia on postpartum day 9. Urgent brain magnetic resonance imaging (MRI) and hormonal studies revealed acute necrosis of the anterior pituitary gland accompanied by multiple endocrine abnormalities. Empirical dexamethasone therapy, initially administered due to clinical suspicion of bacterial meningitis before hormonal study results became available, fortunately resulted in rapid clinical improvement. Although the exact mechanism remains unclear, steroid therapy was successfully tapered and discontinued during hospitalization, allowing the patient to be discharged without ongoing hormonal replacement therapy. Follow-up care revealed continued recovery, with partial empty sella observed on MRI 31months postpartum as a sequela of SS. Conclusion Acute SS may be underrecognized clinically, suggesting a higher incidence than previously reported. Immediate hormonal replacement might be crucial when acute SS is clinically suspected, given the delays in confirmatory testing. Careful monitoring of postpartum patients exhibiting an unusual clinical course should be implemented, as it may facilitate the early detection of potentially life-threatening complications such as adrenal crisis or acute endocrine dysfunction.
proteins
2026-07-30 | The vanishing diagnosis: a comprehensive review of late-onset hypopituitarism due to Sheehan syndrome in resource-limited settings, diagnostic nosography and persistent barriers to endocrine care
Sheehan syndrome (SS), or postpartum pituitary necrosis, is a preventable consequence of obstetrical hemorrhage. Although its incidence has declined in high-income countries, it persists as a major cause of maternal morbidity in low-resource regions, often with diagnostic delays of decades. This review critically analyzes the epidemiological shift of SS, delineates mechanisms permitting delayed presentation, and explores factors contributing to diagnostic oversight in developing nations. We performed a narrative synthesis of literature from 2015-2025, including case series, cross-sectional studies, and reviews on hypopituitarism and neuroimaging, with emphasis on chronic glucocorticoid and thyrotrophin deficiency as clinical masqueraders. In areas with high home-delivery rates, SS prevalence may reach 3% among parous women over 20 years. Mean diagnostic delay ranges from 10-20 years, with extremes up to 50 years postpartum. Common findings include partial empty Sella on magnetic resonance imaging (MRI) and panhypopituitarism, with normocytic normochromic anemia and hyponatremia from adrenal insufficiency as predominant laboratory features. In developing nations, SS serves as a silent marker of obstetric disparities. Its nonspecific symptoms-chronic asthenia, hyponatremia, secondary hypothyroidism-are often misattributed to aging, malnutrition, or psychiatric illness. A high index of suspicion, combined with targeted hormonal assays and appropriate imaging, remains essential to reduce preventable morbidity from this overlooked endocrinopathy.
2026-04-02 | Neuroendocrine Syndromes in Gynecology: A Clinical Review of Asherman Syndrome, Galactorrhea-Amenorrhea, Sheehan Syndrome, and Adrenogenital Syndrome
Neuroendocrine syndromes in gynecology represent a complex interplay between the hypothalamus, pituitary gland, ovaries, and adrenal glands. Disorders such as Asherman syndrome, Galactorrhea-Amenorrhea syndrome, Sheehan syndrome, and Adrenogenital syndrome significantly affect menstrual function, fertility, and hormonal balance.
2025-10-13 | Growth Hormone Therapy Restores Fertility in a Woman With Isolated Growth Hormone Deficiency From Chronic Sheehan Syndrome.
Sheehan syndrome is a rare condition of pituitary necrosis following postpartum hemorrhage, hypovolemia, and/or associated shock, presenting with lactation failure and acute hypopituitarism immediately postpartum; chronic hypopituitarism can manifest months to years later. We present a patient with chronic Sheehan syndrome with isolated growth hormone (GH) deficiency presenting with secondary infertility in whom GH replacement led to natural conception, demonstrating reversibility of infertility. A 38-year-old female patient was referred for secondary infertility on a background of postpartum hemorrhage and inability to breastfeed postpartum 4 years earlier. During workup for secondary infertility, her investigations revealed an isolated GH deficiency, confirmed on a glucagon stimulation test, and a partially empty sella and a thin, 1.6-mm pituitary gland on magnetic resonance imaging, supportive of chronic Sheehan syndrome. Other fertility investigations were unremarkable. Before GH replacement, the patient had 1 unsuccessful cycle of in vitro fertilization. After 2.5 months of GH replacement, the patient achieved natural conception. Individuals with a history of postpartum hemorrhage, agalactorrhea, and symptoms potentially indicative of hypopituitarism should be investigated for chronic Sheehan syndrome. In pituitary pathology, GH deficiency should be considered as a potential contributor to infertility, which can be treated and potentially reversed with GH replacement.
2025-05-01 | A Patient With Post Pulmonary Embolism Syndrome Due to Chronic Thromboembolic Disease
Abstract Introduction:Post-pulmonary embolism syndrome refers to persistent dyspnea, exercise limitation, and impaired quality of life that persist more than 3 months after effective anticoagulation for acute pulmonary embolism. This syndrome includes patients with either chronic thromboembolic pulmonary hypertension (CTEPH); chronic thromboembolic disease (CTED) or post-pulmonary embolism (PE) related dyspnea without identifiable pulmonary vascular disease. We present a case with a history of acute PE with persistent exertional dyspnea, exercise limitation, and poor quality of life since 2018. V/Q SPECT scan revealed multiple bilateral distal filling defects while right heart catheterization (RHC) excluded precapillary pulmonary hypertension (PHT). Case report:72 years old lady known case of panhypopituitarism secondary to Sheehan syndrome, the patient had a history of unprovoked PE in 2018, she received therapeutic anticoagulation, and then she was maintained on apixaban prophylaxis dose. The patient continued to have exertional dyspnea NYHA class 2-3, chest pain, exercise limitation, and fatigue. Physical exam revealed nonobese lady, normal O2 saturation on room air, chest and cardiovascular exam is normal, V/Q SPECT scan revealed multiple bilateral distal filling defects suggestive of chronic PE. Thrombophilia screen, antiphospholipid antibodies, and autoimmune profiles were normal. Echocardiography on different occasions revealed normal left ventricle function with normal ejection fraction, no regional wall motion abnormality, no valvular abnormalities, and mild right ventricular systolic pressure (RVSP) 30-40mmHg. Pulmonary function tests revealed normal spirometry with low DLCO and 6MWD with no significant desaturation, and CT chest revealed no evidence of parenchymal disease. The cardiologist was involved; advised for CT coronaries which came normal. RHC revealed mean pulmonary artery pressure:26mmHg, pulmonary capillary wedge pressure:16mmHg, and pulmonary vascular resistance(PVR): 2 wood units. The picture was suggestive of mild post-capillary PHT; which was attributed to left ventricle disease and the patient was started on anti-failure treatment. Unfortunately, months after treatment, the patient did not show improvement in symptoms. Discussion: This case highlights the importance of follow-up of patients with acute pulmonary embolism, patients with persistent symptoms after 3 months of anticoagulation need further work up including echocardiography to exclude CTEPH, V/Q SPECT scan to look for evidence of chronic PE. Our patient V/Q scan showed evidence of chronic PE and the RHC excluded precapillary pulmonary hypertension with almost normal PVR. We considered our patient to have CTED. As the patient had persistent symptoms even after treatment for possible left-sided heart disease; we believe the patient's symptoms most probably related to post-pulmonary embolism syndrome secondary to CTED.
2025-01-23 | Sheehan syndrome: A case report
Sheehan syndrome or postpartum hypopituitarism is a condition characterized by necrosis of the pituitary gland leading to hormones deficiency. Severe postpartum haemorrhage is the most common cause for the development of Sheehan syndrome.
small molecules
2026-07-25 | Two Decades of Endocrine Silence: Severe Hyponatremia Presenting as Late-Onset Sheehan Syndrome
Sheehan syndrome is a rare but potentially fatal complication of postpartum hemorrhage caused by ischemic necrosis of the anterior pituitary gland. Although its incidence has decreased in countries with comprehensive obstetric care systems, it remains a significant cause of panhypopituitarism in regions lacking timely and adequate access to perinatal care. The clinical challenge lies in its insidious presentation: symptoms develop slowly and gradually, and the diagnosis may remain unrecognized for decades. We report the case of a 52-year-old woman who presented with a one-year history of progressive decline in general health, characterized by debilitating asthenia, somnolence, decreased appetite, and an unintentional 13-kg weight loss. Her obstetric history provided the crucial diagnostic clue: 21 years prior, her last delivery - an initially unattended home birth - was complicated by a retained placenta and severe hemorrhage, followed by total agalactia and permanent secondary amenorrhea. Initial laboratory evaluation revealed severe hyponatremia (119 mmol/L), normocytic anemia, and biochemical evidence of central hypothyroidism and adrenal insufficiency. Magnetic resonance imaging (MRI) confirmed an empty sella turcica. Sequential hormone replacement therapy was initiated - administering glucocorticoids before levothyroxine - resulting in the normalization of serum sodium levels and significant clinical improvement. The clinical triad of postpartum hemorrhage, agalactia, and secondary amenorrhea constitutes a critical diagnostic red flag. Timely recognition of Sheehan syndrome is essential not only for resolving acute complications such as hyponatremia, driven by secondary hypothyroidism and hypocortisolism, but also for preventing cardiometabolic complications and severe osteoporosis with a high fracture risk associated with untreated chronic hypopituitarism.
2025-11-01 | SHEEHAN SYNDROME PRESENTING WITH SEVERE HYPONATREMIA: A CASE REPORT
Sheehan syndrome, characterized by pituitary necrosis secondary to postpartum hemorrhage, results in partial or complete hypopituitarism. Diagnosis is often delayed due to its nonspecific clinical manifestations; however, the condition can lead to life-threatening complications such as hyponatremia. We present the case of a 56-year-old woman admitted with symptomatic severe chronic hyponatremia, who was subsequently diagnosed with panhypopituitarism caused by Sheehan syndrome. The patient was successfully managed with hypertonic saline infusion and hormone replacement therapy (levothyroxine and hydrocortisone). This case emphasizes the importance of obtaining a thorough obstetric history and maintaining a high index of suspicion for Sheehan syndrome in middle-aged women presenting with unexplained hyponatremia.
2025-10-04 | Complete Atrioventricular Block: An Exceedingly Rare Manifestation of Pituitary Crisis in Sheehan Syndrome
This study reports the first case of Sheehan syndrome presenting with complete atrioventricular (AV) block. This life-threatening arrhythmia, associated with glucocorticoid deficiency, can be reversed by glucocorticoid replacement therapy. A 53-year-old female patient presented with complete AV block, elevated myocardial enzyme levels, and hyponatremia. Initially misdiagnosed as having fulminant myocarditis, she received high-dose methylprednisolone therapy, which corrected the complete AV block.
2025-10-01 | Recurrent Symptomatic Hyponatremia Revealing a Late Diagnosis of Sheehan Syndrome and Effectively Treated With Levothyroxine: A Case Report and Brief Review of Literature
ABSTRACT In women with a history of postpartum hemorrhage presenting with chronic symptoms such as hyponatremia, amenorrhea, weight loss, or cold intolerance, suspect Sheehan's syndrome. Early diagnosis and prompt hormonal replacement therapy are essential for reversing complications and improving quality of life. Prioritize evaluation of pituitary function in these patients to ensure timely intervention.
2025-09-29 | Table 1_A case report of acute Sheehan syndrome with a review of 29 existing reports from 1990 to 2024: is it still considered a rare disease?.xlsx
Background Sheehan's syndrome (SS) can occur as a consequence of massive postpartum hemorrhage (PPH). Although traditionally considered rare, acute SS may be underestimated, especially in resource-limited settings, where even minor obstetric complications other than the commonly recognized uterine atony could lead to significant clinical consequences. Case report A 32-year-old pregnant woman (gravida 1, para 0) at 37 weeks and 6 days of gestation developed massive PPH complicated by hemorrhagic shock, cardiac arrest, and an emergent hysterectomy, with an estimated blood loss of 20 L. Despite initial stabilization, the patient experienced acute delirium and hyperpyrexia on postpartum day 9. Urgent brain magnetic resonance imaging (MRI) and hormonal studies revealed acute necrosis of the anterior pituitary gland accompanied by multiple endocrine abnormalities. Empirical dexamethasone therapy, initially administered due to clinical suspicion of bacterial meningitis before hormonal study results became available, fortunately resulted in rapid clinical improvement. Although the exact mechanism remains unclear, steroid therapy was successfully tapered and discontinued during hospitalization, allowing the patient to be discharged without ongoing hormonal replacement therapy. Follow-up care revealed continued recovery, with partial empty sella observed on MRI 31months postpartum as a sequela of SS. Conclusion Acute SS may be underrecognized clinically, suggesting a higher incidence than previously reported. Immediate hormonal replacement might be crucial when acute SS is clinically suspected, given the delays in confirmatory testing. Careful monitoring of postpartum patients exhibiting an unusual clinical course should be implemented, as it may facilitate the early detection of potentially life-threatening complications such as adrenal crisis or acute endocrine dysfunction.
proteins
2026-07-30 | The vanishing diagnosis: a comprehensive review of late-onset hypopituitarism due to Sheehan syndrome in resource-limited settings, diagnostic nosography and persistent barriers to endocrine care
Sheehan syndrome (SS), or postpartum pituitary necrosis, is a preventable consequence of obstetrical hemorrhage. Although its incidence has declined in high-income countries, it persists as a major cause of maternal morbidity in low-resource regions, often with diagnostic delays of decades. This review critically analyzes the epidemiological shift of SS, delineates mechanisms permitting delayed presentation, and explores factors contributing to diagnostic oversight in developing nations. We performed a narrative synthesis of literature from 2015-2025, including case series, cross-sectional studies, and reviews on hypopituitarism and neuroimaging, with emphasis on chronic glucocorticoid and thyrotrophin deficiency as clinical masqueraders. In areas with high home-delivery rates, SS prevalence may reach 3% among parous women over 20 years. Mean diagnostic delay ranges from 10-20 years, with extremes up to 50 years postpartum. Common findings include partial empty Sella on magnetic resonance imaging (MRI) and panhypopituitarism, with normocytic normochromic anemia and hyponatremia from adrenal insufficiency as predominant laboratory features. In developing nations, SS serves as a silent marker of obstetric disparities. Its nonspecific symptoms-chronic asthenia, hyponatremia, secondary hypothyroidism-are often misattributed to aging, malnutrition, or psychiatric illness. A high index of suspicion, combined with targeted hormonal assays and appropriate imaging, remains essential to reduce preventable morbidity from this overlooked endocrinopathy.
2026-04-02 | Neuroendocrine Syndromes in Gynecology: A Clinical Review of Asherman Syndrome, Galactorrhea-Amenorrhea, Sheehan Syndrome, and Adrenogenital Syndrome
Neuroendocrine syndromes in gynecology represent a complex interplay between the hypothalamus, pituitary gland, ovaries, and adrenal glands. Disorders such as Asherman syndrome, Galactorrhea-Amenorrhea syndrome, Sheehan syndrome, and Adrenogenital syndrome significantly affect menstrual function, fertility, and hormonal balance.
2025-10-13 | Growth Hormone Therapy Restores Fertility in a Woman With Isolated Growth Hormone Deficiency From Chronic Sheehan Syndrome.
Sheehan syndrome is a rare condition of pituitary necrosis following postpartum hemorrhage, hypovolemia, and/or associated shock, presenting with lactation failure and acute hypopituitarism immediately postpartum; chronic hypopituitarism can manifest months to years later. We present a patient with chronic Sheehan syndrome with isolated growth hormone (GH) deficiency presenting with secondary infertility in whom GH replacement led to natural conception, demonstrating reversibility of infertility. A 38-year-old female patient was referred for secondary infertility on a background of postpartum hemorrhage and inability to breastfeed postpartum 4 years earlier. During workup for secondary infertility, her investigations revealed an isolated GH deficiency, confirmed on a glucagon stimulation test, and a partially empty sella and a thin, 1.6-mm pituitary gland on magnetic resonance imaging, supportive of chronic Sheehan syndrome. Other fertility investigations were unremarkable. Before GH replacement, the patient had 1 unsuccessful cycle of in vitro fertilization. After 2.5 months of GH replacement, the patient achieved natural conception. Individuals with a history of postpartum hemorrhage, agalactorrhea, and symptoms potentially indicative of hypopituitarism should be investigated for chronic Sheehan syndrome. In pituitary pathology, GH deficiency should be considered as a potential contributor to infertility, which can be treated and potentially reversed with GH replacement.
2025-05-01 | A Patient With Post Pulmonary Embolism Syndrome Due to Chronic Thromboembolic Disease
Abstract Introduction:Post-pulmonary embolism syndrome refers to persistent dyspnea, exercise limitation, and impaired quality of life that persist more than 3 months after effective anticoagulation for acute pulmonary embolism. This syndrome includes patients with either chronic thromboembolic pulmonary hypertension (CTEPH); chronic thromboembolic disease (CTED) or post-pulmonary embolism (PE) related dyspnea without identifiable pulmonary vascular disease. We present a case with a history of acute PE with persistent exertional dyspnea, exercise limitation, and poor quality of life since 2018. V/Q SPECT scan revealed multiple bilateral distal filling defects while right heart catheterization (RHC) excluded precapillary pulmonary hypertension (PHT). Case report:72 years old lady known case of panhypopituitarism secondary to Sheehan syndrome, the patient had a history of unprovoked PE in 2018, she received therapeutic anticoagulation, and then she was maintained on apixaban prophylaxis dose. The patient continued to have exertional dyspnea NYHA class 2-3, chest pain, exercise limitation, and fatigue. Physical exam revealed nonobese lady, normal O2 saturation on room air, chest and cardiovascular exam is normal, V/Q SPECT scan revealed multiple bilateral distal filling defects suggestive of chronic PE. Thrombophilia screen, antiphospholipid antibodies, and autoimmune profiles were normal. Echocardiography on different occasions revealed normal left ventricle function with normal ejection fraction, no regional wall motion abnormality, no valvular abnormalities, and mild right ventricular systolic pressure (RVSP) 30-40mmHg. Pulmonary function tests revealed normal spirometry with low DLCO and 6MWD with no significant desaturation, and CT chest revealed no evidence of parenchymal disease. The cardiologist was involved; advised for CT coronaries which came normal. RHC revealed mean pulmonary artery pressure:26mmHg, pulmonary capillary wedge pressure:16mmHg, and pulmonary vascular resistance(PVR): 2 wood units. The picture was suggestive of mild post-capillary PHT; which was attributed to left ventricle disease and the patient was started on anti-failure treatment. Unfortunately, months after treatment, the patient did not show improvement in symptoms. Discussion: This case highlights the importance of follow-up of patients with acute pulmonary embolism, patients with persistent symptoms after 3 months of anticoagulation need further work up including echocardiography to exclude CTEPH, V/Q SPECT scan to look for evidence of chronic PE. Our patient V/Q scan showed evidence of chronic PE and the RHC excluded precapillary pulmonary hypertension with almost normal PVR. We considered our patient to have CTED. As the patient had persistent symptoms even after treatment for possible left-sided heart disease; we believe the patient's symptoms most probably related to post-pulmonary embolism syndrome secondary to CTED.
2025-01-23 | Sheehan syndrome: A case report
Sheehan syndrome or postpartum hypopituitarism is a condition characterized by necrosis of the pituitary gland leading to hormones deficiency. Severe postpartum haemorrhage is the most common cause for the development of Sheehan syndrome.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
1 orphan drug designation for Sheehan syndrome.
1 orphan drug designation for Sheehan syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated | proteins | FDA | 2022-01-20 | — | Coagulant Therapeutics, Corp. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.